StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s): SZLSF

Healthcare Biotechnology

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.

TSX:SZLS - Post by User

StageZero Life Sciences Ltd > So,

<< Previous

Bullboard Posts

Next >>

Comment by IainCaimbeulon Apr 19, 2024 2:50pm

31 Views

Post# 35998606

RE:RE:RE:RE:So,

Nailbiter2 wrote: I answered your question. The show goes on regardless of the timing of Q4 release.

IainCaimbeul wrote: You added NO info to my question.
Nailbiter2 wrote:
IainCaimbeul wrote: if we have to delay to the end of May 2024 to finally reveal 2023 ye/q4 does that mean stage gets an automatic delay on the mid-May q1 2024?
Asking for a friend.

Tell your friend that YE filings are the only ones that are audited.
If we fail to pay the auditors before May 31st, Q1-24 is still a go for mid May.
Kinda makes Q4-23 redundant at that point... So I've been told.
You and your friend have a pleasant life.